DE60142786D1 - Zusammensetzungen und methoden zur behandlung von candidosen - Google Patents

Zusammensetzungen und methoden zur behandlung von candidosen

Info

Publication number
DE60142786D1
DE60142786D1 DE60142786T DE60142786T DE60142786D1 DE 60142786 D1 DE60142786 D1 DE 60142786D1 DE 60142786 T DE60142786 T DE 60142786T DE 60142786 T DE60142786 T DE 60142786T DE 60142786 D1 DE60142786 D1 DE 60142786D1
Authority
DE
Germany
Prior art keywords
compositions
candidoses
treatment
methods
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60142786T
Other languages
English (en)
Inventor
Robert Clancy
Gerald Pang
Elahi Shokrollah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunter Immunology Pty Ltd
Original Assignee
Hunter Immunology Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ8214A external-priority patent/AUPQ821400A0/en
Priority claimed from AUPQ8294A external-priority patent/AUPQ829400A0/en
Application filed by Hunter Immunology Pty Ltd filed Critical Hunter Immunology Pty Ltd
Application granted granted Critical
Publication of DE60142786D1 publication Critical patent/DE60142786D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60142786T 2000-06-19 2001-06-19 Zusammensetzungen und methoden zur behandlung von candidosen Expired - Lifetime DE60142786D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ8214A AUPQ821400A0 (en) 2000-06-19 2000-06-19 Composition and methods for treatment of candidiasis
AUPQ8294A AUPQ829400A0 (en) 2000-06-22 2000-06-22 Compositions and methods for treatment of candidiasis
PCT/AU2001/000725 WO2001097836A1 (en) 2000-06-19 2001-06-19 Compositions and methods for treatment of candidiasis

Publications (1)

Publication Number Publication Date
DE60142786D1 true DE60142786D1 (de) 2010-09-23

Family

ID=25646360

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60142786T Expired - Lifetime DE60142786D1 (de) 2000-06-19 2001-06-19 Zusammensetzungen und methoden zur behandlung von candidosen

Country Status (10)

Country Link
US (1) US7655248B2 (de)
EP (1) EP1303300B1 (de)
JP (1) JP4933714B2 (de)
KR (1) KR20030016298A (de)
CN (2) CN101862449A (de)
AT (1) ATE476987T1 (de)
BR (1) BR0111785A (de)
CA (1) CA2411912C (de)
DE (1) DE60142786D1 (de)
WO (1) WO2001097836A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146411A (en) * 1998-12-24 2000-11-14 Alsius Corporation Cooling system for indwelling heat exchange catheter
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7858073B2 (en) * 2004-08-17 2010-12-28 Hunter Technology Limited Oral killed vaccines and method for providing same
EP1723965A1 (de) * 2005-05-18 2006-11-22 Stallergenes Sa Zusammensetzungen zur Einleitung antigenspezifischer immunologischer Toleranz durch orale Immunisierung
WO2009013972A1 (ja) * 2007-07-24 2009-01-29 Dainichiseika Color & Chemicals Mfg. Co., Ltd. 免疫アジュバント及びＩｇＡ抗体測定方法
US9180173B2 (en) * 2013-12-09 2015-11-10 Stephanie D. Neider Methods of treating psoriasis using candida antigen
FR3048361B1 (fr) * 2016-03-01 2020-12-18 Biose Compositions pour le traitement des candidoses
CN106635849A (zh) * 2016-11-15 2017-05-10 河北工程大学 一种白色念珠菌感染鸡模型建立的方法
US11273190B2 (en) * 2019-05-06 2022-03-15 Kenda Rigdon Composition of heat-killed yeast and taurine or a phytomedicine for the treatment of chronic inflammation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397839A1 (fr) * 1977-07-18 1979-02-16 Grimberg Georges Compose donnant un vaccin oral intestinal
CH680192A5 (de) * 1989-12-13 1992-07-15 Nestle Sa
JP3510639B2 (ja) * 1991-06-28 2004-03-29 カルピス株式会社 インターロイキン産生能を調節する機能を持たせた機能性食品又は健康食品
GB9417880D0 (en) * 1994-09-06 1994-10-26 Auspharm Int Ltd Vaccine
US5811249A (en) * 1994-10-21 1998-09-22 University Of Utah Research Foundation Control of infectious microorganisms by modulation of chorionic gonadotropin-related protein activity
US5661377A (en) 1995-02-17 1997-08-26 Intraop Medical, Inc. Microwave power control apparatus for linear accelerator using hybrid junctions
JPH09110707A (ja) * 1995-10-12 1997-04-28 Wakamoto Pharmaceut Co Ltd 慢性腎不全改善剤および透析患者のクオリティー オブ ライフ改善剤
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
EP0834322A3 (de) * 1996-10-04 1998-04-22 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Vakzine zur Behandlung von Mycosen
JPH10139674A (ja) * 1996-11-11 1998-05-26 Yakult Honsha Co Ltd インターロイキン１２産生促進剤
US5869290A (en) * 1996-11-21 1999-02-09 Smithkline Beecham Corporation Cayae1 polynucleotides
WO1999017788A1 (en) * 1997-10-06 1999-04-15 Abbott Laboratories Composition of treatment of candidiasis
ATE207755T1 (de) * 1998-04-30 2001-11-15 Vesely Renata Maria Cavaliere Pharmazeutische zusammensetzungen enthaltend lactobacillus brevis und lactobacillus salivarius zur behandlung von vaginainfektionen
US20020009429A1 (en) * 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods

Also Published As

Publication number Publication date
BR0111785A (pt) 2003-05-20
EP1303300B1 (de) 2010-08-11
ATE476987T1 (de) 2010-08-15
CA2411912C (en) 2014-06-17
EP1303300A1 (de) 2003-04-23
CN1443075A (zh) 2003-09-17
JP2004502653A (ja) 2004-01-29
KR20030016298A (ko) 2003-02-26
WO2001097836A1 (en) 2001-12-27
CN101862449A (zh) 2010-10-20
US20040037854A1 (en) 2004-02-26
EP1303300A4 (de) 2004-03-24
JP4933714B2 (ja) 2012-05-16
CA2411912A1 (en) 2001-12-27
US7655248B2 (en) 2010-02-02

Similar Documents

Publication Publication Date Title
ATE296094T1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
NO20034056D0 (no) Proliferative sykdommer
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
NO20055741D0 (no) Nye kjemiske forbindelser
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
IL152450A (en) Compounds and compositions for use in treating tnf-?? mediated conditions
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
TR200200278T2 (tr) Kalsilitik bileşimler
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
DE60105053D1 (de) Zusammensetzungen zur behandlung von gewebe
DE60331654D1 (de) Nicht-radioaktives Strontiummittel zur Behandlung von Krebs
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen